Physician profile
Charles Grubb
NPI 1780644831
$2,233.06
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $1,133 · 2021: $23.17 · 2022: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $337.81 | 2019-2022 | |
| Amarin Pharma, INC. | $286.26 | 2019-2020 | |
| Lilly USA, LLC | $262.53 | 2019-2020 | |
| Allergan, INC. | $171.78 | 2019-2020 | |
| Mylan Specialty L.P. | $152.71 | 2019-2020 | |
| Ibsa Pharma INC. | $129.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $112.04 | 2019-2020 | |
| Novo Nordisk INC | $109.89 | 2019-2020 | |
| Amgen INC. | $106.09 | 2019-2020 | |
| Horizon Therapeutics Plc | $105.45 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.67 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $49.07 | 2019-2020 | |
| Redhill Biopharma INC. | $43.26 | 2020 | |
| Esperion Therapeutics, INC. | $37.05 | 2020 | |
| Philips North America LLC | $29.32 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.24 | 2019 | |
| Abbvie INC. | $27.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $27.17 | 2019 | |
| Genentech USA, INC. | $25.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.46 | 2020 | |
| Pfizer INC. | $14.01 | 2020 | |
| Astellas Pharma US INC | $13.94 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.80 | 2020 | |
| Biodelivery Sciences International, INC. | $13.70 | 2020 | |
| Glaxosmithkline, LLC. | $13.69 | 2020 | |
| Sanofi Pasteur INC. | $13.41 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.09 | 2020 | |
| Aytu Biopharma, INC. | $11.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Grubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.